Lupin licenses European rights to Tenpoint's YUVEZZI for presbyopia
- nuaxia
- il y a 20 heures
- 3 min de lecture
The agreement expands Lupin's European ophthalmology portfolio by adding the first once-daily dual-agent eye drop approved for presbyopia while strengthening its specialty eye care strategy.
Lupin, through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics, a subsidiary of Tenpoint Therapeutics, to commercialise YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the UK, Switzerland, Norway and Iceland.
Under the agreement, VISUfarma will make a strategic investment in Visus, while Tenpoint and Visus become eligible for regulatory and commercial milestone payments and tiered royalties, expanding Lupin's vision care franchise in Europe.
Field | Content |
Alert Type | Deal |
Companies | Lupin Limited; VISUfarma B.V.; Visus Therapeutics Inc.; Tenpoint Therapeutics Holding Limited |
Deal Type | Exclusive licensing agreement and strategic investment |
Asset or Company | YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% |
Therapy Area(s) | Ophthalmology; Presbyopia |
Technology or Modality | Dual-agent ophthalmic solution (carbachol and brimonidine tartrate) |
Deal Value | Financial terms were not disclosed. VISUfarma will make a strategic investment in Visus, while Tenpoint and Visus are eligible for regulatory and commercial milestone payments and tiered royalties on net sales. (Lupin) |
Development Stage | FDA approved; UK regulatory submission under MHRA International Recognition Procedure; additional regional regulatory filings planned. (Lupin) |
Geography | European Union, United Kingdom, Switzerland, Norway and Iceland |
What Happened | On 20 August 2026, Lupin announced that VISUfarma had entered into an exclusive licensing agreement with Visus Therapeutics for the regulatory, commercialisation, marketing, promotion, distribution and sale of YUVEZZI in the licensed European territories. As part of the agreement, VISUfarma will make a strategic investment in Visus, while Tenpoint retains rights outside the licensed territories and remains eligible for milestone payments and royalties. (Lupin) |
Why It Matters | The agreement strengthens Lupin's specialty ophthalmology business following its acquisition of VISUfarma and adds the first once-daily dual-agent eye drop approved for presbyopia to its European portfolio. For Tenpoint, the partnership expands commercial access to YUVEZZI through an established regional eye care business while retaining long-term economic participation through milestones and royalties. (Lupin) |
Supporting Context | YUVEZZI is the first and only approved once-daily dual-agent eye drop for presbyopia. Tenpoint is already commercialising the product in the US following FDA approval and has submitted a Marketing Authorisation Application in the UK through the MHRA's International Recognition Procedure, with additional regulatory submissions planned globally. (Lupin) |
Strategic Rationale | Lupin gains an innovative commercial-stage ophthalmology product that complements its expanding European vision care franchise, while Tenpoint leverages Lupin's commercial infrastructure to accelerate market access across Europe without building its own regional sales organisation. (Lupin) |
Potential Impact | If regulatory approvals are secured across the licensed territories, the agreement could strengthen Lupin's position in specialty ophthalmology and expand patient access to pharmacological treatment for presbyopia across Europe. The commercial impact will depend on regulatory approvals, launch execution and market uptake. (Lupin) |
Key Takeaway | The partnership combines Lupin's growing European ophthalmology infrastructure with Tenpoint's commercial-stage presbyopia therapy, supporting expansion of both companies' presence in the specialty eye care market. (Lupin) |
What to Watch | Regulatory decisions in the UK and other European markets, commercial launch timelines across the licensed territories, and further global regulatory submissions for YUVEZZI. (Lupin) |
Primary Source | |
Relevant Date | 20 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires